3 results
Approved WMOCompleted
As of protocol Amendment 06, evaluation of the safety profile of MLN9708 and/or other study medication is the only endpoint being assessed. All other study endpoints will no longer be assessed.
Approved WMOCompleted
In this study we will investigate how quickly and to what extent ralmitaront is absorbed, transported, and eliminated from the body (this is called pharmacokinetics). Ralmitaront is radioactively labelled with carbon 14 (14C). In this way…
Approved WMOCompleted
The primary objective of this study is to evaluate the short term safety and tolerability, and pharmacokinetic properties of 2-IB when administered to adult patients after OHCA. Secondary objectives include safety and efficacy parameters at 30 days…